introduction
Asia is a heterogeneous region with substantial variability in economic, social and palliative care development. The region has diverse governance within its nations and is of diverse cultural origins and religious affiliations. Some of the region's countries have undergone significant political and social change over the last two decades. Palliative care provision is at varied stages of development throughout the region [1] . Few countries in the region have palliative care policies, and in many parts of the region pain management has been surrounded by myths, cultural bias and attitudes formed from historical experiences with opioids.
Asia carries a disproportionate part of the global burden of liver, esophageal and stomach cancer; with 50-70% of new cases worldwide occurring in Asia [2] . The incidence of lung and breast cancers is rising dramatically. The majority of patients with cancer are diagnosed with advanced-stage disease, and often the only realistic treatment options are pain relief and palliative care. Registry data from the region indicate that the regional burden of cancer continues to increase largely because of an aging and growing local population coupled with an increasing adoption of cancer-causing behaviors, particularly smoking.
Palliative care services throughout the region vary in their development. Singapore, and China-Hong Kong have very developed palliative care programs and have been rated highly in global surveys [3] . Other countries such as Afghanistan, Pakistan, Laos and Cambodia have poorly developed palliative care [1] . But even in some of those nations with well-developed palliative care, opioid consumption has often remained low (Figure 1) .
While the global consumption of opioids has increased, the consumption in most Asian countries has not increased at the same rate. The area included in this report includes countries from two World Health Organization (WHO) regions namely the South East Asian Regional Organization (SEARO) and the Western Pacific Region Organization (WPRO). The morphine consumption in each region is compared with the increase in global consumption over the last 30 years (Figure 2 ). The WPRO increase has largely been due to an increase in opioid consumption in Australia, Japan and South Korea. There has been little increase in opioid consumption in SEARO, a region that includes India, which is considered independently in another report in this supplement [4] .
The Asian Pacific Hospice and Palliative Care Network (APHN) has been active in the region with growth in palliative care in some of the regions of middle-and high-income countries. AHPN and the International Association for the Study of Pain have been working to start national palliative care associations and pain chapters within low-income countries of the region. But many impediments remain throughout the region in making opioids available to cancer patients. This is the first comprehensive study of opioid availability and accessibility for cancer patients in Asia. The countries in the report represent 2515 million of the region's 2612 million people (96%). Afghanistan is also presented with the Middle East [6] , and India is included in a separate paper [4] .
formulary availability and cost of opioids for cancer pain
The availability of opioids and their cost to consumers are summarized in Figure 3 and show great variability throughout the region. Codeine and Morphine were the mostly commonly available formulations. China, Malaysia and the Philippines had all seven medicine formulations available, while five other countries (China-Hong Kong, Japan, South Korea, Thailand and Vietnam) had six of the seven formulations. Cambodia and Laos only had access to injectable morphine, while Kazakhstan had access to only injectable morphine and transdermal (TD) fentanyl. Seven countries (Afghanistan, Bangladesh, Bhutan, Cambodia, Kazakhstan and Laos) did not have oral immediate release (IR) morphine available. Five countries only had access to three formulations (Afghanistan, Bangladesh, Bhutan, Myanmar and Pakistan). Oxycodone IR was available in five countries, and methadone was available in seven countries. Fourteen of 20 countries had access to TD fentanyl.
In approximately half of the countries (11 of 20) , the medicines were provided to patients at no cost or <25% of the 
regulatory restrictions to accessibility
Countries used a range of regulatory restrictions to limit accessibility of opioids. Most countries had considerable restriction and these are detailed below and summarised in Table 12. requirement for permission/registration of a patient to render them eligible to receive an opioid prescription Nine of the twenty countries have no patient restrictions. Six countries (Afganistan, Bangladesh, Kazakhstan, Myanmar, Pakistan and the Philippines) required registration for all three patient categories (i.e., outpatients, inpatients and hospice patients). In China and Vietnam special authority or registration was required only for outpatients, Mongolia required registration for both outpatients and hospice patients ( Figure 5 ).
requirement for physicians and other clinicians to receive a special authority/license to prescribe opioids All physicians are permitted to prescribe opioids in Afghanistan, Bhutan, Cambodia, China-Hong Kong, Indonesia, Japan, Korea, Malaysia, Nepal, Sri Lanka and Thailand. The remaining countries require special authorization for at least one physician group. Bangladesh only allows family doctors to write prescriptions in an emergency situation, while the same applies for surgeons in Mongolia. China does not allow family doctors to prescribe opioids. Nurses are allowed to prescribe with special authority in Bhutan and the Philippines, and in 
requirement for duplicate prescriptions and special prescription forms
Approximately half of the surveyed countries had restrictions on prescription forms. Cambodia, China, Laos, Mongolia, Myanmar, Pakistan, the Philippines and Thailand had restrictive access to these forms, while Cambodia, Mongolia, Pakistan and the Philippines required payment for these prescriptions (Figure 7) .
prescription limits
Half of the countries had limits of ≤2 weeks of opioids. Afghanistan had a 5-day limit, while Cambodia and Laos, China, Mongolia and Myanmar had a 7-day limit. Bangladesh, Kazakhstan, Pakistan and Vietnam had 10-14 day limits. Malaysia allows a maximum supply of up to 60 days, while South Korea and China-Hong Kong have no limits (Figure 8 ).
limitations on dispensing privileges
Most countries reported that opioids were only available in hospital pharmacies. Five countries (Bangladesh, Cambodia, China, Myanmar and Sri Lanka) reported that accessibility to dispensing was very limited (Figure 9 ).
provision for opioid prescribing in emergency situations
An emergency situation is defined as one when there is an immediate need for relieving strong cancer pain but the physician is not able to physically provide a prescription. Examples include a pain crisis at night, on a public holiday or in a remote region. Only in Afghanistan were pharmacists allowed to prescribe in emergency situations. Only five states allowed emergency prescribing by fax or phone, namely Bhutan, Indonesia, Laos, Malaysia and Pakistan (Figure 10 ).
pharmacist privilege to correct technical errors on a prescription
In the situation of a patient presenting with a prescription that contains a technical error (no address, mis-spelling, missing value, etc.), only Bhutan, Japan, South Korea, Laos and Pakistan allowed pharmacists to correct technical errors ( Figure 10 , last column).
use of stigmatizing terminology for opioid analgesics in regulations
Over half the country reporters identified negative language existing in drug laws and half had laws forbidding driving while on opioids (Figure 11 ).
discussion
Cancer continues to be an increasing problem throughout the world with an increase in cancer incidence in low-and middle- Opioid consumption has been documented in various formats for Asian countries [7] [8] [9] . While many countries have shown an increase in consumption since 2000, most countries have 'concerning' consumption as defined by the International Narcotics Control Board (INCB) with a DDD (defined daily doses S-DDD) consumed per million inhabitants per day of <200 mg oral morphine equivalents [9] . The exceptions to this were China-Hong Kong, Japan and South Korea. All surveyed countries in Asia, except South Korea and Japan, have <10% of the anticipated Adequacy of Consumption Measure (ACM) for opioids (Table 1) . ACM was not available for China-Hong Kong.
The approach to improving opioid consumption is guided by the WHO policy guidelines, Ensuring Balance in National Policies on Controlled Substances, Guidance for availability and accessibility of controlled medicines [10] . Moreover, the WHO Palliative Care Strategy states that medication availability, education and government policy must all be addressed and implemented if adequate pain relief and palliative care are to be provided.
medication availability
Approximately half the countries surveyed had limited access to the essential opioids as outlined by the IAHPC [11] . A number of countries have very limited access, particularly access to immediate release oral morphine. It is striking that even in countries with very limited opioid formularies, transdermal fentanyl was often among those formulations available with 14 of the 20 countries having that formulation available. It is widely recognized that pharmaceutical companies and importers are reluctant to invest in the registration and promotion of products, such as immediate release oral morphine or oxycodone that do not generate significant profit. In contrast, where there is room for profit from the promotion and marketing of proprietary products, such as transdermal fentanyl, there is greater commercial motivation.
Oral immediate release morphine has generally been available as tablets throughout the region with less reliance on morphine 
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syrup in Asia compared with other regions (e.g. Africa). Lowincome countries usually rely on importing medications, while high-income countries often manufacture the various formulations within country. Due to import impediments, Nepal, a low-income country, has commenced production of its own immediate and controlled-release morphine [12] .
education
Much work needs to be done in educating both patients and clinicians in the region on the role of opioids in cancer pain.
Many countries have commenced palliative care training in the region. In Japan, palliative care has developed significantly in the last 15 years as part of its comprehensive cancer control plan [13] , including the recent release of new cancer pain guidelines [14] . But in many other counties in Asia, the palliative care knowledge among clinicians has not advanced as effectively. Of 219 Thai physicians, 62.1% had inadequate knowledge and 33.8% had negative attitudes towards opioids for cancer pain relief. The physicians identified both the lack of training opportunities and the periodic shortages of opioids as the greatest barriers to opioid availability [15] .
There are Asian data to suggest that even when physicians have appropriate knowledge there are still barriers to implementation. This was illustrated by a survey of 200 clinicians in the Philippines. In this survey the responding physicians demonstrated a high level of awareness of the WHO analgesic ladder (72%) and the availability of opioids in their areas of practice (89.57%) but only 60% had applied for a license to prescribe opioids. Furthermore, there was a perceived resistance to prescribe strong pure opioid agonists and a preference to use step 2 combination formulations [16] .
Patient concerns regarding the use of opioids for the management of cancer pain have been evaluated in Japan [17] . This study demonstrates the continuing presence of patient barriers and fears regarding the use of opioids to relieve pain.
government policies and regulations
Overall, this study found widespread evidence of overregulation of opioid prescribing for the management of cancer pain. With the exception of Bhutan, Japan, Indonesia Nepal and South Korea, the majority of responding countries in the region reported four or more restrictive regulations that impaired access to opioids for pain relief (Figure 12 ). Indeed, there is an urgent need for regulatory review and the repeal of unnecessarily burdensome barriers to accessibility. The role of policy makers and regulators is critical in opioid availability. A Thai survey of physicians included a survey of 58 policy makers and regulators [15] . Three quarters of the policy makers and regulators had inadequate knowledge regarding the use of opioids in the management of cancer pain and two-thirds had negative attitudes regarding opioid analgesics.
Combined workshops with clinicians and regulators have taken place in the Philippines, Indonesia and Thailand. However, these alone have not resulted in significant increases in opioid consumption within individual countries. Increases in opioid consumption have been seen in two Asian countries that have engaged in the International Pain Policy Fellowship Further strategies for improvement are given in the 'Next steps in access and availability of opioids for the treatment of cancer pain: reaching the tipping point?', the final chapter of this supplement [20] .
conclusion
With the exception of Japan and South Korea, opioid availability continues to be low throughout most of Asia. Formulary deficiencies are severe in several countries, in particular Bangladesh, Myanmar, Afghanistan, Kazakhstan and Laos. Even when opioids are on formulary they are often unavailable, particularly in the same countries. Access is significantly impaired by widespread over regulation that continues to be pervasive across the region.
There are substantial needs for educational initiatives, formulary review, and regulatory review and reform in most of the participating countries in this region. 
